You are here

STTR Phase I Development of Novel Antibacterial and Antifungal Bioadhesive Biomaterials for Diabetic Skin Wound Healing

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R41DK123949-01
Agency Tracking Number: R41DK123949
Amount: $225,000.00
Phase: Phase I
Program: STTR
Solicitation Topic Code: NIDDK
Solicitation Number: PA18-575
Solicitation Year: 2018
Award Year: 2019
Award Start Date (Proposal Award Date): 2019-09-15
Award End Date (Contract End Date): 2020-08-31
Small Business Information
San Antonio, TX 78240-5404
United States
DUNS: 081331216
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 (216) 269-6757
Business Contact
Phone: (216) 269-6757
Research Institution
United States

 Nonprofit College or University

Abstract Diabetic ulcers or pressure ulcers are common for patients with diabetesspinal cord injuriesetcWithout proper managementsuch wounds often lead to infections such as osteomyelitis or sepsisresulting in high mortality and morbidityIn addition to bacterial infectiondiabetic patients are also more susceptible to cutaneous fungal infectionsAdvanced wound dressings and advanced wound therapies should be employed as the severity of infection occurs in diabetic ulcer or even pressure ulcerThis project aims to develop novel collagen citrate based polymer biomaterial medical devices which may find applications in skin wound healingespecially in challenging diabetic skin wound healingOur biomaterial medical devices are potentially unique in terms of dual degradation mechanismenzymatic and hydrolysisbetter reproducibility than biological allograftssustainable anti fungal drug released as a degradation productsutureless wound closure due to strong tissue adhesionand excellent biocompatibilityetcIt is built upon PSU s patented citratebased polymer adhesive and DET s unique collagen electrochemical deposition processIn Aimcrosslinked collagen citrate based polymer of at leastdifferent compositions will be preparedThe resultant collagen citrate polymer biomaterials will be characterized and screened for antimicrobial propertiestissue adhesive propertiescell biocompatibilityin vitro degradabilityCollagenase degradation assay and hydrolysisand mechanical propertiesOne leading collagen citrate based polymer wound matrix will be determinedIn aimProposed leading collagen citrate based polymer matrix will be tested in a diabetic polymicrobial infected skin wound model compared to an FDA approved collagen wound matrix and other controlsWe expect that proposed novel collagen citrate polymer matrix may significantly accelerate the healing of infected diabetic skin wounds compared to controlsThe success of this Phase I STTR may lead to a collagen citrate based polymer matrix positioned for a Phase II studywhich will lead to an advanced wound therapy for reduce the health burden of diabetic skin wounds and even regular skin wounds Narrative This project aims to develop a biomaterial medical device which can stick to the woundrelease drugs to kill bacteria and fungiand help to close and heal the woundsIt fits the NIDDK small business technology transferSTTRtopic HDevelopment of biomaterials that can deliver drugs or biologics to a diabetic foot ulcer to improve healing

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government